Immune Checkpoint Inhibitor
Immune checkpoint inhibitor therapy doubles psoriasis risk
Patients with cancer who received immune checkpoint inhibitors exhibited increased risk for psoriasis compared with those treated with chemotherapy or targeted therapy.
Neoadjuvant immune checkpoint inhibitor therapy improves outcomes in early breast cancer
The addition of immune checkpoint inhibitor therapy to neoadjuvant chemotherapy improved pathologic complete response and EFS for certain patients with early-stage breast cancer, according to a systematic review and meta-analysis.
Typical care resolves respiratory symptoms that come with immune checkpoint inhibitors
BOSTON — Patients with eosinophilic reactive airway disease after immune checkpoint inhibitor therapy saw improved symptoms with typical treatment for reactive airway disease, according to a study presented at the CHEST Annual Meeting.
’Much work remains’ to ensure adequate diversity in trials of immune checkpoint inhibitors
Although progress has been made, lack of diversity continues to be problematic in trials of immune checkpoint inhibitors, according to study results.
Findings reveal ‘crucial’ need to manage immune checkpoint inhibitor-induced myocarditis
Patients with cancer who received immune checkpoint inhibitors rarely developed cardiovascular adverse events, according to results of a systematic review and meta-analysis.
Obesity associated with longer survival in immunotherapy-treated head, neck cancer
An analysis of patients with head and neck squamous cell carcinoma who received immune checkpoint inhibitors showed those with obesity survived longer than those with normal BMI.
Immune-Related Adverse Events
Immunotherapies
Immune-related toxicity from immune checkpoint inhibitors linked to longer survival
Certain individuals with non-cell lung cancer who experienced immune-related adverse events due to immune checkpoint inhibitor therapy had improved survival outcomes, according to retrospective study data published in JAMA Network Open.
Tumor mutational burden may predict immunotherapy response in advanced prostate cancer
Tumor mutational burden may help predict benefit of immune checkpoint inhibitor therapy for men with metastatic castration-resistant prostate cancer, according to retrospective study results.